1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$98.09bn
- HK$101.92bn
- CNY31.83bn
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
Brief: Sino Biopharmaceutical Announces Collaboration With GSK For Respiratory Therapies In China
AstraZeneca secures ex-China license for Sino Biopharmaceutical's experimental COPD drug (updated)
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
Brief: Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721
Brief: Sino Biopharmaceutical Says CDE Accepts NDA For Ropivacaine Hydrochloride Solution
Brief: Sino Biopharmaceutical Says China's CDE Accepts New Drug Application For Tecotabart Vedotin (LM-302)
Brief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
Brief: Sino Biopharmaceutical Says China CDE Accepts New Drug Application For M701 CD3/Epcam Bispecific Antibody
Brief: Sino Biopharmaceutical's Culmerciclib Capsule Receives NMPA Approval For First-Line Hr+/Her2- Advanced Breast Cancer In China
Brief: Sino Biopharmaceutical Says Benmelstobart, Anlotinib Receive NMPA Approval For Advanced ASPS In China
Brief: Sino Biopharmaceutical Says Naldemedine Approved For Marketing In Greater Bay Area
Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 "Pan-Kras Inhibitor" Approved By FDA
Brief: Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment